natgillin/translations-raw huggingface dataset:
204 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
205 Handling of the pen
197 Ravnanje z injekcijskim peresnikom
206 4.8 Undesirable effects
4. 8 Neželeni učinki
207 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
199 Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
208 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
In healthy subjects, the serum half-life of insulin is approximately 4 to 6 minutes.
200 Pri zdravih osebah je razpolovni čas insulina v serumu približno 4 do 6 minut.
In-use pens:
Zdravila Insulin Human Winthrop Comb 25 ne shranjujte v bližini zamrzovalnega razdelka ali zamrzovalnega vložka.
Each cartridge contains 3 balls (stainless steel).
201 3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), batom (iz brombutilne gume (tipa 1)) ter prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
Insulin Human Winthrop Comb 25 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insulin Human Winthrop Comb 25 se ne sme uporabiti, če tega ni mogoče doseči, tj. suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
Insulin Human Winthrop Comb 25 must not be mixed with any other insulin or with insulin analogues.
Insulin Human Winthrop Comb 25 se ne sme mešati z nobenim drugim insulinom ali insulinskimi analogi.
210 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
202 Ravnanje z injekcijskim peresnikom Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
The insulin should be mixed by turning OptiSet slowly up and down at least 10 times.
203 Insulin je treba premešati tako, da OptiSet vsaj 10- krat počasi obrnete navzgor in navzdol.
211 Step 2.
Korak 2.
The injection button allows checking the actual loaded dose.
204 Gumb za injiciranje omogoča preverjanje dejansko napolnjenega odmerka.
212 The patient should be informed on the injection technique by his health care professional.
Pristojni zdravstveni delavec mora bolnika poučiti o načinu injiciranja.
213 1.
205 1.
214 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
206 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 25 in cartridges for OptiClik has been developed for use with OptiClik only.
Insulin Human Winthrop Comb 25 v vložkih za injekcijski peresnik OptiClik je pripravljen samo za uporabo v injekcijskih peresnikih OptiClik.
215 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
207 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
216 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
208 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
217 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
209 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
218 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
210 Občasni: urtikarija na mestu injiciranja Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
219 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
211 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
The cartridge in-use (in the insulin pen) or carried as a spare may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Rok uporabnosti po prvi uporabi vložka Vložek, ki ga uporabljate ali ga imate pri sebi za rezervo, lahko shranjujete največ 4 tedne pri temperaturi do 25 °C zaščiteno pred neposredno toploto ali svetlobo.
220 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in s prirobljeno zaporko (iz aluminija), z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
Packs of 3, 4, 5, 6, 9 or 10 cartridges for OptiClik are available.
212 Na voljo so pakiranja s 3, 4, 5, 6, 9 ali 10 vložki za injekcijski peresnik OptiClik.
Insulin pen The cartridges for OptiClik are to be used in conjunction OptiClik only and as recommended in the information provided by the device manufacturer.
Vložki za injekcijski peresnik OptiClik se uporabljajo samo skupaj z injekcijskim peresnikom OptiClik in po navodilih izdelovalca peresnika.
221 Insulin Human Winthrop Comb 25 cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Vložki Insulin Human Winthrop Comb 25 za injekcijski peresnik OptiClik niso zasnovani tako, da bi dovoljevali mešanje kakšnega drugega insulina v vložku za injekcijski peresnik OptiClik.
222 1.
214 1.
Alternatively, it may emerge gradually over a period of several weeks.
215 Po drugi strani pa se lahko pojavi postopoma med obdobjem več tednov.
223 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
224 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
216 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
225 Handling of the pen
217 Ravnanje z injekcijskim peresnikom
226 4.8 Undesirable effects
4. 8 Neželeni učinki
227 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
219 Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
228 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
In healthy subjects, the serum half-life of insulin is approximately 4 to 6 minutes.
220 Pri zdravih osebah je razpolovni čas insulina v serumu približno 4 do 6 minut.
229 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
221 3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
230 Handling of the pen
222 Ravnanje z injekcijskim peresnikom
231 Step 2.
223 Korak 2.
EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX
224 EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX
233 1.
225 1.
Insulin Human Winthrop Comb 50 100 IU/ ml suspension for injection in a vial
Insulin Human Winthrop Comb 50 100 i. e. / ml suspenzija za injiciranje v viali
Insulin Human Winthrop Comb 50 is a biphasic isophane insulin suspension consisting of 50% dissolved insulin and 50% crystalline protamine insulin.
Insulin Human Winthrop Comb 50 je dvofazna suspenzija insulina izofana, sestavljena iz 50% raztopljenega insulina in 50% kristalnega protamin- insulina.
234 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
226 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 50 contains 100 IU of insulin per ml suspension.
En mililiter suspenzije Insulin Human Winthrop Comb 50 vsebuje 100 i. e. insulina.
235 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
227 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
236 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
228 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Insulin Human Winthrop Comb 50 can be used during breastfeeding.
Zdravilo Insulin Human Winthrop Comb 50 je med dojenjem dovoljeno uporabljati.
237 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
229 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
238 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
General disorders and administration site conditions
230 Splošne težave in spremembe na mestu aplikacije
Insulin Human Winthrop Comb 50 (a biphasic isophane insulin suspension with 50% dissolved insulin) is an insulin with rapid onset and moderately long duration of action.
Insulin Human Winthrop Comb 50 (dvofazna suspenzija insulina izofana s 50% raztopljenega insulina) je insulin s hitrim začetkom in zmerno dolgim trajanjem delovanja.
Following subcutaneous injection, onset of action is within 30 minutes, the phase of maximum action is between 1.5 and 4 hours after injection and the duration of action is 12 to 16 hours.
Delovati začne v 30 minutah po subkutanem injiciranju, največji učinek doseže od 1, 5 do 4 ure po injiciranju in deluje od 12 do 16 ur.
239 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
5.3 Preclinical safety data
231 5. 3 Predklinični podatki o varnosti
240 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
6.6 Special precautions for disposal and other handling
232 6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Insulin Human Winthrop Comb 50 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the vial.
Insulina Insulin Human Winthrop Comb 50 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno viale.
As with all insulin preparations, Insulin Human Winthrop Comb 50 must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Tako kot velja za vse pripravke insulinov, tudi zdravila Insulin Human Winthrop Comb 50 ne smete mešati z raztopinami, ki vsebujejo reducente, npr. tiole ali sulfite.
Insulin Human Winthrop Comb 50 may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Comb 50 se sme mešati z vsemi humanimi insulini, ki jih izdeluje Sanofi - Aventis, NE pa s tistimi, ki so posebej pripravljeni za uporabo v insulinskih črpalkah.
Insulin Human Winthrop Comb 50 must also NOT be mixed with insulins of animal origin or with insulin analogues.
Zdravila Insulin Human Winthrop Comb 50 prav tako NE smete mešati z insulini živalskega izvora ali insulinskimi analogi.
242 1.
233 1.
Insulin Human Winthrop Comb 50 40 IU/ ml suspension for injection in a vial
Insulin Human Winthrop Comb 50 40 i. e. / ml suspenzija za injiciranje v viali
Each ml contains 40 IU insulin human (equivalent to 1.4 mg) of the active substance.
En mililiter vsebuje 40 i. e. humanega insulina.
243 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
234 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 50 contains 40 IU of insulin per ml suspension.
En mililiter suspenzije Insulin Human Winthrop Comb 50 vsebuje 40 i. e. insulina.
244 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
235 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
245 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
236 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
246 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
237 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
247 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
238 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
248 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
239 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
249 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Before withdrawing insulin from the vial for the first time, remove the plastic protective cap.
240 Pred prvim izvlekom insulina iz viale odstranite plastično zaščitno zaporko.
251 1.
241 1.
Insulin Human Winthrop Comb 50 100 IU/ ml suspension for injection in a cartridge
Insulin Human Winthrop Comb 50 100 i. e. / ml suspenzija za injiciranje v vložku
252 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
242 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 50 in cartridges has been developed for use in the OptiPen series.
Insulin Human Winthrop Comb 50 v vložkih je pripravljen za uporabo v injekcijskih peresnikih OptiPen.
253 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
243 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
254 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
244 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Insulin Human Winthrop Comb 50 can be used during breastfeeding.
Zdravilo Insulin Human Winthrop Rapid je med dojenjem dovoljeno uporabljati.
255 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
245 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
256 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
General disorders and administration site conditions
246 Splošne težave in spremembe na mestu aplikacije
257 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
5.3 Preclinical safety data
247 5. 3 Predklinični podatki o varnosti
258 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom i( z brombutilne gume (tipa 1)) in prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
Packs of 3, 4, 5, 6, 9 or 10 cartridges are available.
248 Na voljo so pakiranja s 3, 4, 5, 6, 9 ali 10 vložki.
Cartridges Before insertion into the pen, Insulin Human Winthrop Comb 50 must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred vstavitvijo v injekcijski peresnik mora biti Insulin Human Winthrop Comb 50 1 do 2 uri na sobni temperaturi, potem pa ga je treba za preverjanje vsebine ponovno suspendirati.
Insulin Human Winthrop Comb 50 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insulin Human Winthrop Comb 50 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
259 Any unused product or waste material should be disposed of in accordance with local requirements.
249 Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
260 1.
250 1.
Insulin Human Winthrop Comb 50 100 IU/ ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 50 100 i. e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
Insulin Human Winthrop Comb 50 is a biphasic isophane insulin suspension consisting of 50% dissolved insulin and 50% crystalline protamine insulin.
Insulin Human Winthrop Comb 50 je dvofazna suspenzija insulina isofana, sestavljena iz 50% raztopljenega insulina in 50% kristalnega protamin- insulina.
The need to adjust (e. g. reduce) the dose may become evident immediately after transfer.
251 Potreba po prilagoditvi (npr. zmanjšanju) odmerka se lahko pokaže takoj po prehodu.
261 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
252 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
262 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
263 Handling of the pen
253 Ravnanje z injekcijskim peresnikom
OptiSet has to be used as recommended in these Instructions for Use (see section 6.6).
Optiset uporabljajte kot je priporočeno v navodilih za ravnanje z OptSetom (glejte poglavje 6. 6).
264 Hypoglycaemia, in general the most frequent undesirable effect of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.
Pojavi se, če je odmerek insulina prevelik glede na potrebo po insulinu.
265 General disorders and administration site conditions
255 Splošne težave in spremembe na mestu aplikacije
266 5.3 Preclinical safety data
256 5. 3 Predklinični podatki o varnosti
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Zdravila ne smemo mešati z drudimi zdravili razen s tistimi, ki so omenjena v poglavju 6. 6.
Store in a refrigerator (2°C – 8°C).
Injekcijski peresniki, ki jih ne uporabljate Shranjujte v hladilniku (2 °C - 8 °C).
267 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3- ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in
Each cartridge contains 3 balls (stainless steel).
257 brombutilne gume (tipa 1)).
Before first use, Insulin Human Winthrop Comb 50must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred prvo uporabo mora biti Insulin Human Winthrop Comb 50 1 do 2 uri na sobni temperaturi; potem ga je treba za preverjanje vsebine ponovno suspendirati.
Insulin Human Winthrop Comb 50 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insulin Human Winthrop Comb 50 se ne sme uporabiti, če tega ni mogoče doseči, tj. suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
Insulin Human Winthrop Comb 50 must not be mixed with any other insulin or with insulin analogues.
Insulin Human Winthrop Comb 50 se ne sme mešati z nobenim drugim insulinom ali insulinskimi analogi.